Bristol-Myers Squibb Company Release: New Data Demonstrate Significant Improvement in Progression-Free Survival for Triple Negative Metastatic Breast Cancer Patients Treated with IXEMPRA(TM) Plus Capecitabine

SAN ANTONIO--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced new data from studies of IXEMPRA™ (ixabepilone) plus capecitabine compared to capectabine alone, including a pre-specified sub set analysis demonstrating a significant increase in progression free survival (PFS) in patients with triple negative breast cancer.